Results 101 to 110 of about 382,033 (356)

Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]

open access: yes, 2016
Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana   +5 more
core   +3 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Early-onset basal cell carcinoma

open access: yesThe Turkish Journal of Pediatrics, 2013
Basal cell carcinoma (BCC) is a common skin cancer that is responsible for approximately 75% of non-melanoma skin cancers. BCC occurs on sunexposed areas in fair-skinned individuals; frequency increases with age and peaks in the seventh decade of ...
Enver Turan   +3 more
doaj  

Giant basal cell carcinoma associated with vitiligo

open access: yesClinical Case Reports, 2019
We report a woman with two giant Basal cell carcinomas (BCCs) on the back, the largest with 12 cm in diameter, inside a vitiligo plaque. They were metatypical subtype BCC associated with a nodular subtype area.
Luiza Fiszon‐Cerqueira   +5 more
doaj   +1 more source

Deep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma

open access: hybrid, 2022
Chisato Ohe   +11 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

DERMOSCOPIC DIAGNOSTIC CRITERIA IN DIFFERENT MORPHOLOGICAL TYPES OF BASALIOMA

open access: yesAlʹmanah Kliničeskoj Mediciny, 2016
Background: Basal cell carcinoma of the skin (BCC, basalioma) is one of the most common malignant skin tumors. Dermoscopy is the most available today method of non-invasive diagnosis of skin tumors.
A. N. Khlebnikova, N. V. Novoselova
doaj   +1 more source

Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. [PDF]

open access: yes, 2019
BackgroundPlexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction.
Banerjee, Sudeep   +9 more
core   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

open access: yesMolecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy